Search Results 1-10 of 12706 for SC

  1. Kimberly G. Blumenthal, M.D., M.Sc. - Doctors and Medical Staff - Mayo Clinic

    Blumenthal, M.D., M.Sc. Allergist-Immunologist. Request an Appointment · Overview. Departments. Pulmonary Medicine · Allergic Diseases. Location. Jacksonville ...

  2. A Study of SC-007 in Subjects With Advanced Cancer - Mayo Clinic

    This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC ...

  3. Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer - Mayo Clinic

    SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. Participation eligibility. Participant ...

  4. A Study of SC-006 in Subjects With Advanced Cancer - Mayo Clinic

    Part A (dose regimen finding) will involve dose escalation and possible dose interval modification to define the maximum tolerated dose (MTD) and/or recommended ...

  5. A Study of SC‑004 in Subjects With Advanced Solid Tumors - Mayo Clinic

    In Part B (dose expansion), potential therapeutic doses may be studied with SC-004 as monotherapy and SC-004 in combination with ABBV-181 in disease-specific ...

  6. Michael Camilleri, M.D., D.Sc. - Mayo Clinic Faculty Profiles

    Irritable bowel syndrome and chronic constipation. These conditions account for 25 percent of all patients presenting to gastroenterologists. Dr. Camilleri ...

  7. Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy - Mayo Clinic

    Secondary objectives include efficacy measures of efgartigimod PH20 SC in participants with IIM. IIM is a disease of the immune system that causes weakness of ...

  8. Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease - Mayo Clinic

    The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab SC) as maintenance treatment in participants with moderately to ...

  9. Study of Sc-FOS for Pouchitis Prevention - Clinical Trials

    The main objective is to compare prebiotic therapy with placebo for the prevention of pouchitis after closure of diverting ileostomy in patients with an ileal ...

  10. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

    Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult ...